Mycobacterium tuberculosis (Mtb) executes a plethora of immune-evasive mechanisms, which contribute to its pathogenesis, limited efficacy of current therapy, and the emergence of drug-resistant strains. This has led to resurgence in attempts to develop new therapeutic strategies/targets against tuberculosis (TB). We show that Mtb down-regulates sirtuin 1 (SIRT1), a nicotinamide adenine dinucleotide (NAD + )-dependent deacetylase, in monocytes/macrophages, TB animal models, and TB patients with active disease. Activation of SIRT1 reduced intracellular growth of drugsusceptible and drug-resistant strains of Mtb and induced phagosome-lysosome fusion and autophagy in a SIRT1-dependent manner. SIRT1 activation dampened Mtb-mediated persistent inflammatory responses via deacetylation of RelA/p65, leading to impaired binding of RelA/p65 on the promoter of inflammatory genes. In Mtb-infected mice, the use of SIRT1 activators ameliorated lung pathology, reduced chronic inflammation, and enhanced efficacy of anti-TB drug. Mass cytometry-based high-dimensional analysis revealed that SIRT1 activation mediated modulation of lung myeloid cells in Mtb-infected mice. Myeloid cell-specific SIRT1 knockout mice display increased inflammatory responses and susceptibility to Mtb infection. Collectively, these results provide a link between SIRT1 activation and TB pathogenesis and indicate a potential of SIRT1 activators in designing an effective and clinically relevant host-directed therapies for TB.
INTRODUCTION
Tuberculosis (TB) pathogenesis is driven by a complex interplay between the host immune system and the survival strategies of the bacterium (1) . The ability of Mycobacterium tuberculosis (Mtb) to persist in protected niches within the body delays the efficacy of current antibiotic therapy, contributing to the emergence of multidrug-resistant (MDR) strains. Therefore, the development of new therapeutic strategies, such as host-directed therapies (HDTs) that enhance Mtb-specific immunity, are urgently needed (2, 3) .
An effective host immune response is important for the containment of persistent Mtb infection (4) , and this is intimately linked to the metabolic programs of the host (5) . The engagement of cellular immunometabolic circuits is predominantly regulated by sensors, including mTOR (mammalian target of rapamycin), AMPK (adenosine monophosphate-activated protein kinase), and the sirtuins (silent mating type information regulation 2 homologs) (6) (7) (8) . Perturbations in mTOR and AMPK signaling have been associated with Mtb virulence (9, 10) . Targeting the mTOR pathway with specific inhibitors has been shown to stimulate autophagy induction, leading to increased mycobacterial clearance (3, 11) . Similarly, activation of AMPK using the antidiabetic drug metformin leads to improved Mtb control (12) . This highlights the potential of targeting functional connections between host immune defense and metabolism to modulate Mtb pathogenicity.
The sirtuins are a family of nicotinamide adenine dinucleotide (NAD + )-dependent class III histone deacetylases, consisting of seven members present in nearly all subcellular compartments (8) . Among these, sirtuin 1 (SIRT1) is involved in a range of cellular processes important for the maintenance of human health, including stress response, cellular metabolism, and aging (13, 14) . SIRT1 is known to be important in the prevention of viral diseases (13, 15) ; however, its role in chronic bacterial infections is unknown.
In the present study, we show that SIRT1 expression is downregulated during active Mtb infection and that enhancement of SIRT1 activity using specific activators inhibits the intracellular growth of Mtb, normalizes the inflammatory response, enhances the efficacy of isoniazid (INH; a first-line anti-TB drug), and limits disease immunopathology.
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sets of Mtb-infected cells ( fig. S1 , B and C) (16) . A time-dependent reduction of SIRT1 mRNA expression was also observed in the lung tissues of Mtb-infected mice (Fig. 1C ). Higher SIRT1 expression was observed in the lesions of Mtb-infected macaques with latent TB compared with active disease (Fig. 1D) . Immunostaining of the granulomas of Mtb-infected macaque lung sections further showed higher levels of SIRT1 in the bacillus Calmette-Guérin (BCG)-vaccinated macaques than in unvaccinated animals ( Fig. 1, E and F) . These SIRT1-expressing cells were mainly macrophages and not T cells ( fig. S2) .
To evaluate the clinical significance of Mtb-mediated SIRT1 down-regulation, we performed a pairwise comparison of SIRT1 mRNA expression profiles derived from peripheral blood of active TB (ATB) patients, latent TB individuals, and healthy controls from seven different cohorts (table S1) (17) (18) (19) (20) (21) (22) . In the UK 2010, South Africa 2010 (17) , and South Africa 2013 (22) cohorts, SIRT1 mRNA levels were lowest in ATB patients compared with healthy and latent TB individuals (Fig. 1 , G and H, and fig. S1D ). SIRT1 mRNA levels were also reduced in HIV patients with TB as comorbidity compared with those with HIV alone (South Africa 2014 cohort; Fig. 1I ) (21) . In TB patients undergoing chemotherapy (18, 20) , SIRT1 mRNA levels increased after 2 to 3 months of therapy and reached levels comparable with those observed in healthy/latent TB individuals by the sixth month of treatment ( Fig. 1J and  fig. S1 , E and F). Furthermore, human monocyte-derived macrophages (hMDMs) from ATB patients also displayed reduced SIRT1 mRNA expression (fig. S1G) (19) . In all, these results indicate (i) an important disease-related effect of Mtb infection on SIRT1 expression and (ii) an association of lower SIRT1 expression with TB pathogenesis.
SIRT1 activation restricts intracellular Mtb growth and induces autophagy and phagosome-lysosome fusion
To determine whether SIRT1 is essential for controlling mycobacterial growth, SIRT1-deficient cells were infected with Mtb and were found to display higher bacillary loads ( Fig. 2A) , suggesting that activating SIRT1 may control mycobacterial growth. Enhancing SIRT1 activity by resveratrol (RES; a natural activator) and SRT1720 (SRT; a synthetic activator) (23, 24) using concentrations that are not toxic for cells ( fig. S3 , A and B) inhibited the growth of intracellular BCG ( fig. S3C ) and Mtb in THP-1 cells (Fig. 2 , B to D) and hMDMs ( fig. S3D ) in a dose-and time-dependent manner. This effect was abolished in cells where SIRT1 was genetically (Fig. 2E) or chemically (fig.  S3E ) inactivated. RES and SRT also restricted intracellular replication of Mtb MDR strains (Fig. 2F) . Inhibition of mycobacterial growth by SIRT1 and (F) to (I) are analyzed by Mann-Whitney U test. Data in (J) are analyzed by paired Wilcoxon signed-rank test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Exact P values are provided in table S7. to (E) and (I) to (L) are representative of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 by two-tailed Student's t test. Exact P values are provided in table S8.
Mtb-infected

activation was further validated with SA3, an additional SIRT1 activator ( fig. S3F ). SIRT1 activity is primarily dependent on the availability of intracellular NAD + (25, 26) . In our experiments, Mtb infection reduced the intracellular NAD + /NADH ratio, which was reversed by the addition of SIRT1-activating compounds ( fig. S3G) . Notably, SRT activation increased the levels of SIRT1 mRNA in Mtb-infected cells ( fig. S3H) , consistent with earlier studies (23, 27) .
To identify the possible mechanism(s) underlying the restriction of intracellular Mtb growth by SIRT1 activators, we performed a genome-wide transcriptional analysis using total RNA isolated from Mtb-infected THP-1 cells in the presence or absence of RES. At 24 hours after infection, a total of 8766 genes were differentially expressed in response to infection ( fig. S4A ). RES treatment altered the expression of 6325 genes in Mtb-infected cells ( fig. S4A ), of which 71% (4486 of 6325) overlapped with those affected by infection. RES reversed the expression pattern of 3062 of these genes (quadrants X and Y in fig.  S4B and table S2). Analysis of these 3062 genes identified the enrichment of genes that regulate autophagy and phagosome-lysosome fusion (P = 4.76 × 10 −5 ), indicating the induction of innate antimicrobicidal cellular functions upon SIRT1 activation (Fig. 2G) . Indeed, in mycobacteriainfected cells, SRT-mediated SIRT1 activation induced autophagy as assessed by up-regulation of LC3 (Fig. 2H and fig. S5A ) and generation of its lipidated form (Fig. 2I) . This SRT-mediated autophagy induction was not observed in Mtb-infected SIRT1 −/− cells (Fig. 2, H and I) , and blocking autophagy abolished SRT-mediated restriction of mycobacterial growth (Fig. 2J) . Furthermore Mtb-infected SIRT1 −/− cells were found to display less LC3 puncta ( fig. S5B ). SIRT1 activation by SRT or RES also led to an increase in fluorescent BCG accumulation in LysoTracker Red (LTR)-labeled compartments (Fig. 2, K Together, these data indicate that SIRT1 activation contributes to the control of mycobacterial growth by inducing autophagy and phagosomelysosome fusion.
SIRT1 activation normalizes Mtb-induced inflammatory responses by deacetylating RelA/p65
To further delineate the effect of SIRT1 activation, we performed Gene Ontology (GO) analysis on 3062 RES-modulated genes ( fig. S4B ). This indicated enrichment of GOs involved in the inflammatory response, DNA damage restoration, telomere maintenance, and viral defense responses (Fig. 3 , A and B, and table S3). A similar trend was observed when 3062 genes were analyzed using Ingenuity Pathway Analysis (IPA). Pathways such as triggering receptor expressed by myeloid cell 1 (TREM-1) signaling, liver X receptor (LXR) activation, interferon signaling, and nuclear factor B (NF-B) signaling were associated with genes up-regulated by infection and down-regulated by RES ( fig. S4C and table S4). These data suggest that RES results in the normalization of inflammation-associated genes and pathways, modulated by Mtb (12, 17, 28) . Consistent with the effects of RES, treatment of Mtb-infected THP-1 cells with SRT reduced mRNA and protein expression of inflammatory cytokines (Fig. 3 , C and D) and RelA/p65 (Fig. 3 , E to G), which is a subunit of NF-B, a known target of SIRT1 (29) . Here, SRT treatment led to decreased RelA/p65 acetylation in Mtb-infected THP-1 cells (Fig. 3, F and G) . Chromatin immunoprecipitation (ChIP) assays revealed that Mtb infection enhanced the occupancy of RelA/p65 on tumor necrosis factor- (TNF), interleukin-1B (IL1B), IL6, and monocyte chemoattractant protein-1 (MCP-1) promoters, which was reversed by SRT (Fig. 3H) . These results indicate that SIRT1 activation-mediated deacetylation of RelA/p65 is important for the unoccupancy of RelA/p65 on the promoter of proinflammatory genes, leading to the attenuation of Mtb-induced inflammatory responses.
SIRT1 activation restricts Mtb growth in mice
To determine whether SIRT1 is essential for controlling Mtb growth in vivo, myeloid cell-specific SIRT1 knockout (Mac-SIRT1 KO) mice (30) were infected with Mtb and were found to display higher bacillary loads compared with wild-type controls (Fig. 4A ). We next evaluated the efficacy of RES and SRT in mouse models of acute and chronic TB (12) . In an acute model of Mtb infection, RES and SRT inhibited the growth of Mtb in the lungs and spleens of infected wild-type mice (Fig. 4 , B and C, and fig. S6A ). When SRT was administered in combination with INH, a greater proportion of mice with no detectable colony-forming units (CFU) in the tissues was detected compared with mice receiving INH alone (Table 1) . Consistent with our findings in vitro ( fig. S3H ), we also observed an increase in SIRT1 mRNA levels in the lungs of Mtb-infected mice upon SRT treatment ( fig. S6B) . In a chronic model of TB, SRT alone inhibited the growth of Mtb in the lungs (Fig. 4D) , and mice treated with INH in combination with SRT showed decreased bacillary loads in the lungs compared with mice receiv ing INH alone (Table 1) . These results indicate that activation of SIRT1 restricts Mtb growth and can enhance Mtb clearance by anti-TB drugs.
SIRT1 activators reduce Mtb-mediated tissue pathology and inflammation in mice
We next assessed the effect of RES and SRT treatments on tissue pathology. Histologic examination of the lungs from untreated control mice at 35 days after infection revealed diffuse coalescent lesions, with numerous infiltrating macrophages and lymphocytes, and large number of intracellular acid-fast bacilli (AFB; Fig. 5A ). At this time, RES-treated mice displayed reduced levels of AFB and slightly smaller granulomatous lesions (Fig. 5A ), previously linked with improved Mtb control in mice (12, 31, 32) . Morphometric analysis showed the reduced percentage of lung parenchyma area involvement in the pathology in RES-treated mice compared with untreated animals (43.8% versus 55.6%, respectively; 
SIRT1 activation modulates the lung myeloid landscape in
Mtb-infected mice Infiltration of myeloid cells expressing inflammatory cytokines and chemokines into the tissues is a major characteristic of TB progression in mice (33) . Because we observed reduced pathological inflammation in the lungs of SRT-treated, Mtb-infected mice (Fig. 5) , we investigated the profile of pulmonary myeloid cells. Lung cells from infected and uninfected mice, with or without SRT treatment, were stained with a panel of 37 markers (table S5) and analyzed using cytometry by time-offlight (CyTOF) (34, 35) . We first verified the panel antibodies for their binding to the lung cells ( fig. S7) (35) . Analysis of CD45 + CD90 − CD3 − CD19 − lung cells using nonlinear dimensionality reduction technique tSNE (t-distributed stochastic neighbor embed ding) in conjunction with a machine-learning updated clustering algorithm (DensVM) (35) identified 28 distinct cell clusters with shared surface marker expression characteristics (Fig. 6A and fig. S8 ). We assessed the accuracy of the machine-learning automated gating by validating each cluster using manual gating ( fig. S9A ), overlaying each cluster on its respective parent §Number of mice with no detectable CFU out of total number of animals in that group (in bracket, percentage information is provided). ║In a chronic TB model bacterial load (CFU) in the lung of INH or SRT + INH-treated mice after 2 weeks of treatment.
¶Mean CFU values (n = 5). Difference in CFU values between INH and SRT + INH group is significant (P = 0.0317 by Mann-Whitney U test). fig. S10B) , as identified by tSNE anal ysis (Fig. 6A and fig. S8 ).
Unbiased analysis of 28 clusters distinguished uninfected, infected, and SRT-treated, infected animals ( Fig. 6B and fig. S11A ). Nineteen of 28 clusters were found to be statistically significant enriched or depleted in Mtb-infected animals (Fig. 6B) (Fig. 6, A and B, and  fig. S8 ). We confirmed the differential abun dance of these cell subsets using manual gating (Fig. 6C and fig. S11 , B and C). SRT treatment had minimal effect on uninfected animals as indicated by mixed clustering of cells from uninfected animals, with or without SRT treatment (Fig. 6B ).
SIRT1 activation impairs Ly6C monocytes in the mouse lung
Our high-dimensional analysis revealed that SRT treatment of Mtbinfected animals normalized 6 of the 19 disease-associated clusters toward the frequency present in the lungs of uninfected mice (Fig. 6 (Fig. 6D and fig. S11D ). Of particular interest was the decreased abundance of CD11b lo F4/80 + monocytes (Ly6C lo or Ly6C + ) in the lungs of SRT-treated, Mtb-infected mice compared with untreated, Mtbinfected mice, confirmed by manual gating (Fig. 6E ) and verified using fluorescence flow cytometry (Fig. 6, F and G, and fig. S9B ). In contrast, Mtb-infected Mac-SIRT1 KO mice displayed an increased percentage and number of CD11b lo F4/80 + (Ly6C lo or Ly6C + ) monocytes in the lungs compared with wild-type mice as early as day 3 after infection ( fig. S11E and Fig. 6H, respectively) . Overall, our data indicate an association of SIRT1 activity/expression with myeloid cell frequency in the lungs of Mtb-infected mice, relevant for the control of Mtb growth and inflammation.
DISCUSSION
Mtb has coevolved with the human immune system, acquiring an unexpected ability to exploit cellular host factors and circumvent immunity for its own survival (1) . In this study, we show that active Mtb infection suppresses SIRT1 (a conserved mammalian NAD + -dependent deacetylase) expression and reduces cellular NAD + pool, which is required for SIRT1 activity (26, 36, 37) . Depletion of cellular NAD + could be due to a toxin secreted by Mtb that leads to host cell death and Mtb dissemination (38) . We showed that SIRT1-activating compounds inhibited the intracellular growth of Mtb; activated host cell autophagy and phagosome-lysosome fusion; and reduced Mtb growth, tissue pathology, and chronic inflammation in mice. SIRT1 has been described to play a role in the regulation of autophagy (39) and can also directly affect AMPK activity (40) , which we and others have recently shown to be clinically beneficial (11, 12, 41) . Thus, the capacity of both SIRT1 and AMPK to modulate innate immune mechanism and inflammation (42, 43) emphasizes the importance of the SIRT1-AMPK axis in (i) rewiring the host antimicrobial arsenal and (ii) skewing the immunopathological balance toward protective immunity against Mtb, leading to enhanced host benefits (2, 3, 12) .
TB pathogenesis is associated with early infiltration of myeloid cells into infected tissues (33) . Inconsistencies in the naming and working definitions of myeloid cell subsets have complicated the objective description and quantification of cellular innate immune responses. Using a previously described unbiased high-dimensional analysis (35) monocytes upon SIRT1 activation could also favor SRT-mediated Mtb control. The recruitment of Ly6C monocytes into the tissues occurs via engagement of the chemokine receptor CCR2 with MCP-1 (CCL2) (46), a chemokine regulated by SIRT1. Together, our data provide new insights into the plasticity/heterogeneity of myeloid cells during Mtb infection (47) and suggest a role of SIRT1 activators in controlling Mtb growth/pathogenesis by regulating myeloid cell infiltration.
SIRT1 activators have a favorable safety profile and are currently being tested in phase 2 human trials (https://ClinicalTrials.gov) (48) . Therefore, their usage as TB HDT could have important clinical implications through (i) avoiding the development of resistance by targeting the host and not the pathogen, (ii) shortening the course of multidrug therapy for TB, and (iii) improving anti-Mtb immune responses to facilitate pathogen clearance. Also, because SIRT1 activators modulate chronic inflammation, they could prevent long-term pulmonary morbidity due to lung destruction in TB patients (47) . However, to fully decipher the applicability of SIRT1 activators as potential TB HDTs, several issues remains to be addressed. First, our study does not describe the effect of SIRT1 activators on the adaptive immune response, which is important in controlling Mtb infection. Second, the exact dialog between SIRT1-deficient myeloid cells and TB pathogenicity remains unclear. Third, studies in other animal models such as macaques are warranted, possibly through the use of next-generation SIRT1 synthetic activators.
Overall, our study demonstrates an important role of SIRT1 in the Mtb infection-associated immunopathogenesis. Moreover, the study adds to our understanding of the lung myeloid cell heterogeneity and possible cross-talk of immunologic and metabolic pathways during Mtb infection, and suggests the potential of targeting SIRT1 for the development of innovative next-generation HDTs to improve TB treatment outcomes.
MATERIALS AND METHODS
Study design
The objective of this study was to assess the effect of Mtb infection on host sirtuins, which regulate the range of immunometabolic processes. Our experiments indicated that Mtb modulates SIRT1 in monocytes/ macrophages, mice, and macaques. Next, we evaluated the efficacy of SIRT1 activators against Mtb infection in mouse TB model and performed detailed mechanistic studies using in vitro and mouse models to precisely delineate the antimicrobial and anti-inflammatory function of SIRT1. Last, the clinical significance of Mtb-mediated SIRT1 downregulation was evaluated by mining the SIRT1 mRNA expression profiles from peripheral blood of ATB patients, latent TB individuals, and healthy controls from seven different cohorts. All experiments were performed at least twice. Each in vitro experiment was performed in duplicates/triplicates, and data of three to five independent experiments were presented. In mouse experiments, animals were randomly distributed among different groups. For histopathological analysis, pathologist was blinded for the groups.
Reagents
The following chemicals were used: SRT HCl (ApexBio, #A4180), RES (Sigma-Aldrich, #711004), SA3 (Santa Cruz Biotechnology, #SC-222315), EX527 (Selleckchem, #S1541), and INH (Sigma-Aldrich, #I3377). The following antibodies were used: anti-SIRT1 (Millipore, #07-131; Abcam, #E104), anti-NF-B p65 (Santa Cruz Biotechnology, #SC-372), anti-NF-B p65 (acetyl K310) (Abcam, #ab19870), anti-LC3B (Cell Signaling Technology, #3868), anti-CD3 (Dako, #A0452), anti-CD68 (Dako, #M0814), anti-CD163 (Serotec, #MCA1853), anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (14C10) (Cell Signaling Technology, #2118), anti-rabbit immunoglobulin G (IgG), horseradish peroxidase (HRP)-linked antibody (Cell Signaling Technology, #7074), and mouse anti-rabbit IgG (conformation-specific) monoclonal antibody (Cell Signaling Technology, #3678). Stealth SIRT1 small interfering RNAs (siRNAs) (set of three: #HSS118729, #HSS177403, and #HSS177404) and control siRNAs (#1299001) were from Life Technologies and Integrated DNA Technologies, respectively.
THP-1 cell culture
Human monocyte THP-1 cells from the American Type Culture Collection were maintained in RPMI 1640 (Gibco) supplemented with 10% heat-inactivated fetal bovine serum (FBS), 1% sodium pyruvate, 1% l-glutamine, 1% nonessential amino acids, and 1% kanamycin at 37°C in a 5% CO 2 humidified atmosphere. In infection experiments, no antibiotic was used.
Preparation of hMDMs
Peripheral blood mononuclear cells were isolated from total blood using a Ficoll gradient followed by enrichment of monocytes using CD14 magnetic beads (Miltenyi Biotec). The purified CD14 + monocytes were resuspended in RPMI 1640 with 10% FBS, 1% penicillin, 2 mM l-glutamine, and human macrophage colony-stimulating factor (M-CSF; 100 ng/ml; R&D Systems) and incubated at 37°C in 5% CO 2 for 6 days. The medium was changed on the fourth day. On day 6, differentiated macrophages were harvested and cultured overnight without M-CSF. On day 7, cells were washed and used for experiments. Blood collection from healthy volunteers was approved by the Institutional Review Board, National Healthcare Group Domain (Singapore).
Culture of mycobacterial strains
Mtb H37Rv, HN878, CDC1551, Erdman, W148, AH30, CC13, AI10, and KY strains; Mycobacterium bovis BCG; and M. bovis BCG-green fluorescent protein (GFP) were grown in Middlebrook 7H9 broth (BBL Microbiology Systems) supplemented with albumin-dextrose-catalase (ADC; Difco Laboratories) and 0.05% Tween 80 at 37°C for 5 to 7 days to an OD 600 (optical density at 600 nm) of 0.4 to 0.5. After this, mycobacterial cells were pelleted, resuspended in fresh 7H9 broth with 20% glycerol, and stored at −80°C. One vial of the stock was thawed to enumerate CFU per milliliter. On the day of infection, the cells were thawed, washed, and sonicated before use. Drug-resistant strains were maintained at the Public Health Research Institute (Newark, NJ).
Infection of cells with mycobacteria
Frozen Mycobacterium strains were thawed, washed, resuspended in antibiotic-free RPMI 1640 with 10% FBS, and used to infect cells with a multiplicity of infection of 5. The infected cells were incubated at 37°C in 5% CO 2 for 3 hours. After this, cells were washed twice with antibiotic-free medium, counted, seeded in triplicate, and either left untreated or treated with different compounds for the indicated time periods. For inhibition experiments, mycobacteria-infected cells were pretreated with the SIRT1 inhibitor EX527 or autophagy inhibitors for 0.5 hours before addition of SIRT1 activators. At predetermined time points after infection, the cells were lysed for enumerating mycobacteria. THP-1 cells were differentiated for 16 to 18 hours using 4 M phorbol 12-myristate 13- Transfection of siRNAs THP-1 cells were transfected with siRNAs using the Lipofectamine 2000 Kit (Invitrogen) according to the manufacturer's protocol. Knockdown was confirmed by Western blotting. All transfection data are means ± SEM of three independent experiments, performed in duplicate.
Western blot
Protein lysates from cells were obtained by lysis in radioimmunoprecipitation assay buffer (Sigma) with protease (Roche) and phosphatase (Roche) inhibitors. A Micro BCA Protein kit (Thermo Scientific) was used to measure protein levels, and equal amounts of proteins were resolved by electrophoresis on 12% tris-HCl gels (Mini-PROTEAN TGX gels; Bio-Rad) and transferred onto polyvinylidene difluoride membranes (Trans-Blot Turbo Transfer Pack; Bio-Rad). Membranes were developed using the indicated primary antibody at a 1:1000 dilution and secondary antibodies at a 1:3000 dilution in blocking solution. This was followed by incubation with Chemiluminescent HRP detection reagent (Millipore) for 1 min before image acquisition.
ChIP assay
ChIP assays were performed using the anti-NF-B p65 antibody (C-20) or normal rabbit IgG, with the SimpleChIP Plus Enzymatic Chromatin IP Kit (Cell Signaling Technology, #9005), following the standard protocol. DNA fragments were subjected to quantitative reverse transcription polymerase chain reaction (qRT-PCR) using primers flanking NF-B response elements on various targets. ChIP qRT-PCR data analysis was performed as previously described (49) .
Measurement of M. bovis BCG in lysosomes
THP-1 cells were infected with GFP-conjugated BCG. After infection, cells were incubated with 500 nM LTR (Invitrogen) in the presence or absence of drugs for 4 or 24 hours. Cells were then washed with phosphate-buffered saline (PBS) and fixed in 4% paraformaldehyde for 20 min at room temperature. Fixed cells were then washed with PBS. Fluorescence intensities of GFP-BCG and LTR were analyzed using an Olympus FV1000 confocal microscope. Z-stacks of cells were acquired and quantitated.
Autophagy analysis
Anti-LC3 antibody was used for flow cytometric analysis and Western blotting at a dilution of 1:250 and 1:1000, respectively. As a positive control, cells were treated with 2.5 M rapamycin or 1 M INH for 4 or 24 hours.
Mouse models of infection with Mtb
The antitubercular activity of SRT and RES was evaluated in an acute and chronic infection model of C57BL/6 mice (12) . Female C57BL/6 mice (6 to 8 weeks old) were infected aerosolly with Mtb H37Rv or Erdman. Three to four animals were sacrificed on day 1 to determine the number of bacteria implanted in the lungs. Treatment was initiated 7 or 40 days after infection in the acute and chronic model, respectively. Drugs were administered by gavage once a day, 6 days a week. Mice were sacrificed at predetermined time points followed by harvesting of tissues and enumeration of Mtb CFU. A total of seven experiments (five acute and two chronic) were performed. All mice were housed in a biosafety level 3 (BSL3) laboratory and treated humanely. The Mac-SIRT1 KO mice (30) were a gift from X. Li (U.S. National Institute of Environmental Health Sciences). A total of three experiments were performed with Mac-SIRT1 KO and their littermate controls.
Enumeration of Mtb CFU in infected mice
The mycobacterial load in the lung and spleen of infected mice was quantified by plating tissue homogenates on Middlebrook 7H11 agar supplemented with oleic acid-ADC (OADC). At predetermined time points, mice were euthanized, and organs were aseptically excised, washed in PBS, and homogenized in PBS containing 0.25% Tween 80 using a MACS tissue dissociator (Miltenyi Biotec). A series of dilutions of tissue homogenate were plated in triplicate. Agar plates were incubated at 37°C for 3 weeks, after which colonies were counted visually. CFU obtained from two or three dilutions were used to calculate the total number of CFU per tissue per mouse.
CyTOF marker labeling, flow cytometry, data acquisition, and analysis Lung cells were stained with heavy metal isotope-labeled antibodies (table S5) (50) , barcoded, and acquired on CyTOF 1 (Fluidigm). Samples were debarcoded using manual gating in FlowJo, and analysis of live CD45
− myeloid cells was carried out using the tSNE dimension reduction and DensVM density-based clustering algorithm (35) . Flow cytometry was performed to validate CyTOF data (in independent experiment) and to assess the infiltration of myeloid cells in Mtb-infected Mac-SIRT1 KO mice (see Supplementary Methods for details on mass cytometry and flow cytometry).
Histology and morphometry
The upper right lobes of mouse lungs were fixed in 10% buffered formalin and paraffin-embedded. Sections were stained with hematoxylin and eosin (H&E) or Ziehl-Neelsen acid-fast stain and were photographed in a Nikon Microphot-FX photomicrographic system with NIS-Elements F3.0 software (Nikon Instruments Inc.). Morphometric analysis of lung involvement in pathology was performed using PathScan Enabler IV slide scanner (Meyer Instruments) and SigmaScan Pro 5 (SPSS Science Inc.) image analysis system. The area of all lesions in a section was measured first, and then the percentage from the area of the whole section was calculated (lung involvement).
Immunohistochemistry of macaque lung sections Slides (5 m thick) were cut from formalin-fixed, paraffin-embedded tissue blocks; subjected to double-antigen retrieval; and stained with SIRT1, CD3, CD68, and CD163 antibodies. Detection was performed with an anti-rabbit MACH 3 Rabbit AP-Polymer Kit (Biocare), and slides were counterstained with YO-PRO nuclei stain (Molecular Probes). The images were taken on a CRi microscope and counted using INFORM software. Only those cells that exhibited a SIRT1 signal at least 15 arbitrary units bright from each nucleus were considered positive and included for quantification.
Real-time quantitative PCR
Cells were lysed in TRIzol (Invitrogen), and total RNA was isolated using the RNeasy Mini Kit (Qiagen). RNA was reverse-transcribed using the iScript cDNA Synthesis Kit (Bio-Rad). Complementary DNA (cDNA) was used for real-time quantitative PCR (RT-qPCR) using 2× iQ SYBR Green Supermix and iCycler (Bio-Rad). The primers are described in table S6. The mRNA expression levels in infected cells per tissue were normalized to GAPDH expression, and fold induction was calculated by the C T method relative to those in uninfected cells per tissue. RT-qPCR was performed in triplicate.
Microarray analysis
Total RNA from uninfected and Mtb-infected THP-1 cells, treated or untreated with 100 M RES for 24 hours, was extracted using the mirVana Isolation Kit (Life Technologies). RNA quality was confirmed using the Agilent Bioanalyzer, and only samples with RNA integrity number >7 were processed. Biotinylated complementary RNA was prepared from 100 ng of total RNA using the Epicentre TargetAmp Nano-g Biotin-aRNA Labeling Kit for the Illumina system, followed by hybridization on Illumina human arrays. Raw expression data were extracted by GenomeStudio Gene Expression v1.9.0 and processed with quantile normalization (51) . Hierarchical clustering analysis with complete linkage algorithms was performed using R (52) . Heat maps were plotted using Spotfire (TIBCO Software Inc.; http://spotfire.tibco.com/). Differential expression analysis was performed using Linear Models for Microarray Data (LIMMA) (52) . GO analysis was carried out by DAVID. Pathway analysis was carried out using IPA (Ingenuity Systems; www. ingenuity.com).
Gene expression analysis of macaque granulomas
Granuloma samples were collected from animals infected with a moderate dose of Mtb CDC1551 (50 to 100 CFU) via aerosol, which resulted in the development of either ATB or latent TB infection (LTBI). These samples were used for isolation of total RNA and subjected to host transcriptomics using rhesus macaque-specific microarrays (Agilent) relative to normal lung tissue derived from uninfected macaques as baseline, as described earlier (53) . Control lung samples were labeled with Cy3, whereas lesion samples were labeled with Cy5 and cohybridized on arrays (54) . Data were normalized using locally weighted scatterplot smoothing, and data specific for SIRT1 were analyzed across the matrix and hierarchically clustered using Spotfire DecisionSite for microarray analysis (http://spotfire.tibco.com/).
Cytokine analysis
Enzyme-linked immunosorbent assays (ELISAs) for IL-1, IL-6, and MCP-1 were performed on THP-1 cell culture supernatants using human cytokine/chemokine-specific ELISA kits (eBioscience and BioLegend) as per manufacturers' instructions. Lung homogenates were assayed by Luminex 100 using Exponent 3.2 software and Milliplex MAP for Luminex xMAP Technology Assay (MCYTOMAG-70K Mouse Cytokine 32-Plex; Millipore).
Human cohort SIRT1 gene expression profiles were retrieved from Gene Expression Omnibus. Eight publicly available clinical data sets of whole-blood gene expression profiles from ATB patients (n = 201), individuals with LTBI (n = 191), healthy controls (n = 18), patients with TB undergoing therapy at various time points (n = 38), and patients with other diseases (n = 110) were analyzed (table S1).
Statistical analysis
All values are means ± SEM of individual samples. Data analysis was performed with GraphPad Prism Software (GraphPad Software Inc.) using Student's t test and Mann-Whitney U test (when samples are not normally distributed) for two groups and analysis of variance (ANOVA) for multiple groups. Human expression data were analyzed by MannWhitney U test between patient groups or by paired Wilcoxon signedrank test.
Study approval
The study was approved by the Institutional Biosafety Committee and the Institutional Animal Care and Use Committee of the Biological Resource Council (BRC), the Agency for Science, Technology and Research (A*STAR; Singapore), the Defence Science Organisation (DSO; Singapore), and the University of Massachusetts Med ical School.
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